This could represent a significant breakthrough for clinicians as a new gold-standard imaging test for treatment stratification and tracking TAM response in upcoming CD47 mAb immunotherapy trials of osteosarcomas and other solid tumors. The gene discussed is CD47; the disease is osteosarcoma.